Immunome (Immunome) 6-1 Month Momentum % : 187.22% (As of Apr. 29, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Immunome 6-1 Month Momentum %?

6-1 Month Momentum % is the total return of the stock from 6-month ago to 1-month ago. As of today (2024-04-29), Immunome's 6-1 Month Momentum % is 187.22%.

The industry rank for Immunome's 6-1 Month Momentum % or its related term are showing as below:

IMNM's 6-1 Month Momentum % is ranked better than
94.55% of 1522 companies
in the Biotechnology industry
Industry Median: 4.02 vs IMNM: 187.22

Competitive Comparison of Immunome's 6-1 Month Momentum %

For the Biotechnology subindustry, Immunome's 6-1 Month Momentum %, along with its competitors' market caps and 6-1 Month Momentum % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immunome's 6-1 Month Momentum % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunome's 6-1 Month Momentum % distribution charts can be found below:

* The bar in red indicates where Immunome's 6-1 Month Momentum % falls into.

Immunome (NAS:IMNM) 6-1 Month Momentum % Calculation

6-1 Month Momentum % is calculated as following:

6-1 Month Momentum %

( Price 1-month ago

Price 6-month ago

- 1 )

100 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Immunome (NAS:IMNM) 6-1 Month Momentum % Explanation

Momentum investing is a trading strategy in which investors buy securities that are rising and sell before the prices start to go back down. The 6-1 Month Momentum % measures the total return to a stock over the past six months, but ignores the previous month.

The reason why the most recent month’s return dropped related to the short-term reversal effect associated with momentum. There is an academic finding that short-term momentum actually has a reversal effect, whereby the previous winners (measured over the past months) do poorly the next month, while the previous losers do well the next month. In order to eliminate the short-term reversal effect, the previous month return was not included in this calculation.

Immunome 6-1 Month Momentum % Related Terms

Thank you for viewing the detailed overview of Immunome's 6-1 Month Momentum % provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunome (Immunome) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunome Inc (NAS:IMNM) » Definitions » 6-1 Month Momentum %

Comparable Companies

Traded in Other Exchanges

N/A

Address

665 Stockton Drive, Suite 300, Exton, PA, USA, 19341

Website

https://www.immunome.com

Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The company's primary focus areas are oncology and infectious disease, including COVID-19. It primarily operates in the U.S. Its current programs comprise Oncology (IMM-ONC-01), SARS-CoV-2 (IMM-BCP-01), and IMM20059 Anti-EPN1.

Executives

Jean Jacques Bienaime	director	925 PAGE MILL ROAD, PALO ALTO CA 94304
Robert Lechleider	officer: Chief Medical Officer	C/O IMMUNOME, INC., 665 STOCKTON DRIVE, SUITE 300 PA 19341
Max Rosett	officer: SVP Operations	C/O MORPHIMMUNE INC., 101 FOUNDRY DRIVE, SUITE 1200, WEST LAFAYETTE IN 47906
Clay B Siegall	director, officer: President and CEO	21823 30TH DR SE, BOTHELL WA 98021
Jack Higgins	officer: Chief Scientific Officer	C/O MORPHIMMUNE INC., 101 FOUNDRY DRIVE, SUITE 1200, WEST LAFAYETTE IN 47906
Isaac Barchas	director, other: See remarks	1601 BRYAN STREET, SUITE 4141, DALLAS TX 75201
Bruce Turner	officer: Chief Strategy Officer	C/O MORPHIMMUNE INC., 101 FOUNDRY DRIVE, SUITE 1200, WEST LAFAYETTE IN 47906
James P Boylan	director	C/O ENAVATE SCIENCES, 2884 SAND HILL RD., STE 100, MENLO PARK CA 94025
Matthew K Robinson	officer: Chief Technology Officer	C/O IMMUNOME, INC., 665 STOCKTON DRIVE SUITE 300, EXTON PA 19341
Michael Rapp	director, 10 percent owner	712 FIFTH AVENUE, 49TH FLOOR, NEW YORK NY 10019
Franklyn G Prendergast	director
Michael Lefenfeld	director	IMMUNOME, INC., 665 STOCKTON DRIVE, SUITE 300, EXTON PA 19341
Purnanand D Sarma	director, officer: President and CEO	IMMUNOME, INC., 665 STOCKTON DRIVE, SUITE 300, EXTON PA 19341
John L Lamattina	director	81 WYMAN ST, POST OFFICE BOX 9046, WALTHAM MA 02454
Philip Wagenheim	director	712 FIFTH AVENUE, 49TH FLOOR, NEW YORK NY 10019